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ABSTRACT
We conducted a randomized, double blind, placebo-controlled multi-institutional trial to assess the ability of
amifostine to protect patients against acute lung injury associated with cyclophosphamide/cisplatin/carmustine
(BCNU) (STAMP I), a BCNU-containing high dose chemotherapy regimen used with hematopoietic cell
transplantation. Amifostine was administered in a dose of 740 mg/m2 for 2 doses preceding administration of
BCNU, the presumed pulmonary-toxic component of the regimen. The trial was stopped after 79 patients were
randomized and a planned interim analysis demonstrated that it was unlikely that pulmonary cytoprotection
would be detected with further accrual. We conclude that amifostine, used in the dose and schedule we tested,
does not reduce the incidence of acute lung injury produced by STAMP I. Further, we suggest that amifostine
use with BCNU in other contexts and with clinically achievable doses is unlikely to protect the lung from
BCNU-associated acute injury.
© 2004 American Society for Blood and Marrow Transplantation
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[NTRODUCTION
Amifostine (Ethyol, Medimmune, Gaithersburg,
D; WR-2721) is a phosphorylated sulfhydryl analog
f glutathione, the major intracellular protectant
gainst electrophilic reactive intermediates [1]. Its
ood and Drug Administration–approved indication
s protection against cisplatin-induced renal tubular
njury [2]. Additionally, randomized controlled trials
ave provided evidence for protection against radia-
ion-induced xerostomia and mucositis [3], cisplatin-
nduced peripheral neuropathy [2], and neutropenia
rom cyclophosphamide [2]. There are also clinical
hase II data supporting protection against melpha-
an-associated mucositis [4], ototoxicity from cisplatin
5], and esophagitis from radiation [6], as well as other
issue-protective effects. Both preclinical and clinical
ata provide strong evidence that these effects are b
76roduced without tumor protection in vivo [7,8]. Fi-
ally, preclinical data suggest that amifostine can react
ith electrophilic intermediates of most alkylating
gents and, perhaps, with reactive intermediates pro-
uced by other classes of antineoplastic agents such
s anthracyclines [7]. Taken together, available data
upport the conclusion that amifostine can produce
linically important cytoprotection without compro-
ising the antitumor effect during a variety of che-
otherapy and radiation treatment programs.
Carmustine (BCNU) is an alkylating agent that is
sed extensively in high-dose chemotherapy regimens
iven with hematopoietic cells. In high doses, BCNU
roduces acute lung injury that is steroid responsive
ut that can be fatal, particularly if diagnosis is delayed
9,10]. The incidence of this lung injury varies widely
etween regimens, with a previously reported approx-
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Acute Lung Injury and Amifostine
Bmate range of 5% to 55% [11-13]. BCNU continues
o be used, however, because of its antitumor potency
nd lack of gastrointestinal mucosal toxicity, a fre-
uent side effect of hematopoietic transplant regi-
ens. Thus, this toxicity is clinically important for
atients undergoing hematopoietic cell transplanta-
ion.
We hypothesized that the use of amifostine with
n intensive BCNU-containing chemotherapy regi-
en would reduce the incidence of BCNU-associated
cute lung injury seen with the regimen. For this
urpose, we used the regimen of cyclophosphamide/
isplatin/BCNU (STAMP I), which contains a large
ose (600 mg/m2) of BCNU. This regimen is well
escribed to produce acute lung injury in 30% to 55%
f patients treated [10]. To test the hypothesis, we
onducted a randomized, double-blind, placebo-con-
rolled trial at 3 institutions (University of Colorado,
tanford University, and Karmanos Cancer Center/
ayne State University) familiar with the STAMP I
egimen and diagnosis of the acute lung injury it
roduces.
ATIENTS AND METHODS
ligibility and Treatment
Patients eligible for this trial had a biopsy-proven
iagnosis of stage II to IV breast cancer and were
reated with the STAMP I regimen. They received
yclophosphamide 1875 mg/m2/d for 3 consecutive
ays as a 1-hour infusion, cisplatin 55 mg/m2/d for 3
onsecutive days as a continuous infusion, and BCNU
00 mg/m2 as a 2-hour infusion administered imme-
iately after completion of the cisplatin. All drugs
ere administered through a central venous catheter.
f BCNU or amifostine resulted in clinically relevant
ypotension, a saline infusion and dopamine were
sed to augment blood pressure. Antiemetic support
as that routinely used by the individual transplant
rograms.
Additional eligibility criteria included acceptable
epatic, renal, and cardiac function. In the case of
ulmonary function, all patients were required to have
diffusing capacity of the lung for carbon monoxide
DLCO) and forced expiratory volume in 1 second
60% of the predicted value. Other eligibility criteria
ere those dictated by the chemotherapy protocol
tself and have been previously described [14]. This
tudy was approved and monitored by the Colorado
ultiple Institutional Review Board and the Stanford
niversity and Karmanos Institutional Review
oards. All patients gave and signed written informed
onsent before participation in this study.
mifostine Administration
Amifostine 740 mg/m2 per dose or placebo was
dministered as two 5-min infusions beginning 90 and b
B&MT0 minutes, respectively, before the BCNU infusion
as started. Amifostine was infused through a lumen
f the central venous catheter separate from the che-
otherapy. Amifostine was prepared by each hospi-
al’s inpatient pharmacy, and equivalent intravenous
uid without amifostine was used as placebo. Physi-
ians, physician extenders, and nursing and data man-
gement staff were blinded to the identity of the ad-
inistered agent. Although provision to unblind the
taff in case of a signiﬁcant adverse event was present,
t was never used. Alza Pharmaceuticals (Palo Alto,
A) provided the amifostine used in this study.
atient Evaluation and Trial Design
This trial was designed as a 3-phase study, with
nterim evaluations between phases. The objective of
he ﬁrst (feasibility) phase was to treat 3 patients at
ach institution with STAMP I plus amifostine in the
xact dose and schedule proposed for the trial and to
onﬁrm that the regimen was tolerable. This phase
as completed at the collaborating institutions, and
o unanticipated or intolerable adverse effects related
o amifostine were noted. During the second (ran-
omized treatment) phase, 80 patients were to be
ccrued, and their treatment was to be randomized to
ither amifostine or placebo. An interim evaluation of
utcome was prospectively planned and performed
fter all patients had been followed up for at least 6
onths from treatment. If the interim evaluation had
een positive, a third (efﬁcacy) phase was planned with
nrollment of an additional 80 patients. In fact, the
rial was stopped after the second phase in view of the
tatistical likelihood that additional accrual would not
ead to a positive result, as discussed below.
efinition of Acute Lung Injury
For the purposes of this study, acute lung injury
as suspected whenever a study subject developed
ew dyspnea, either at rest or exercise, or when ab-
ormal pulmonary function testing was noted without
ymptoms. If the patient was symptomatic, exercise
ulse oximetry or pulmonary function testing was per-
ormed. Either of 2 ﬁndings would indicate possible
cute lung injury, even if these tests were performed
outinely without symptoms: (1) a 25% decrease in
LCO when compared with either the pre–bone
arrow transplant or discharge DLCO, whichever
as the more recent, or (2) a 7% decrease in blood
xygen saturation with maximal exercise, as measured
y pulse oximetry.
Further, confounding factors that might produce
yspnea, such as infection, poor cardiac function, clin-
cally evident embolism, and severe anemia, must be
bsent. Patients who developed possible acute lung
njury while neutropenic were required to undergo
ronchoscopy or lung biopsy to eliminate infectious
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2auses of pulmonary abnormality. Thus, patients iden-
iﬁed as having possible pulmonary gas exchange de-
ects in the absence of signs of infection or circulatory
ysfunctions were eligible for enrollment in this study.
istologic proof of acute lung injury was not required
or study entry.
It was recommended that all these patients receive
mpiric corticosteroid therapy. At the time of acute
ung injury, many of these patients had returned home
rom the transplant center, and thus the pattern of
reatment varied widely. As a result, no attempt was
ade to evaluate treatment outcome in these patients.
ccrual and Statistical Methods
After the initial 9 patients were accrued to the
hase I feasibility pilot study (these patients were not
ncluded in the efﬁcacy analysis), 79 patients were
ccrued, and in 78 their administered treatment was
andomized to amifostine or placebo. An 80th patient
as not accrued to avoid confusion between 2 collab-
rating centers and inadvertent overenrollment. One
atient was enrolled, but chemotherapy complications
efore the administration of BCNU and amifostine
aused the patient not to be treated with the study
rug. This patient was not included in the analysis.
egistration and randomization were performed by
sing a secure Internet site with password protection.
ollow-up data on the occurrence of acute lung injury,
uration of observation, and survival were collected in
he same manner.
The initial planned phase II and III accrual of 160
atients was determined assuming a 50% relative re-
uction in the incidence of acute lung injury from
mifostine. The assumed baseline incidence of acute
ung injury from STAMP I was in the range of 30% to
5%, so a baseline rate of 40% was used for statistical
urposes. We likewise assumed that failure to reduce
he incidence to20% was not a clinically meaningful
esult. On the basis of a 1-tailed signiﬁcance level of
 .05 and a power of 0.8, the proposed sample size
hould have provided a detectable beneﬁt from ami-
ostine with the Fisher exact test.
The interim analysis after phase II was completed,
nd all patients were observed for at least 6 months. At
his point, the data were examined for the incidence of
cute lung injury. A total of 75% of the amifostine
roup and 66% of the placebo group had developed
cute lung injury within this period. A total of 85% of
he amifostine group and 89% of the placebo group
ere alive at this time. In both cases, beneﬁt seemed to
ccrue to the placebo group, although neither of these
ifferences was statistically signiﬁcant. There was no
igniﬁcant difference in the average age at which treat-
ent began: 38.6 years for amifostine and 40.45 years
or placebo. s
78harmacokinetic Analysis
To evaluate the possibility that amifostine might
lter the pharmacokinetics (PK) of BCNU, 17 patients
andomized to placebo and 14 patients randomized to
mifostine (all from the University of Colorado) un-
erwent comprehensive PK blood sampling and anal-
sis. Blood sampling, analytical analysis, and modeling
ere performed as described previously [15]. Win-
onlin (Pharaight Corp, Mountain View, CA) was
sed for noncompartmental PK modeling. Derived
K parameters for the 2 groups were compared by
sing the Fisher exact test.
ESULTS
Patient characteristics are shown in Table 1 (pla-
ebo versus amifostine). These data demonstrate that
here was balance by disease stage and patient age
mong the 3 participating sites. Seventy (90%) of the
8 patients who participated in this trial were treated
or primary breast cancer. The mean age of patients in
his study was 46 years. The mean age of patients who
eveloped acute lung injury was identical to that of
hose who did not (46 years). In addition, Table 1
ummarizes the intervals between STAMP I treat-
ent and the diagnosis of acute lung injury by cohort.
he mean time from treatment to diagnosis was 63
ays and did not differ between the placebo and ami-
ostine-treated groups.
Amifostine can produce hypotension when used
ith conventional chemotherapy, as does BCNU in
he STAMP I regimen. There was concern that the
ature of this side effect and the dosing proposed
ight result in unacceptable hypotension or delays or
missions of BCNU dosing. In fact, none of these
roblems occurred, and all treated patients received
ull doses of study drug and BCNU at the prescribed
imes. It should be noted that all patients were receiv-
ng hyperhydration (250 mL/m2/h) during the period
hese drugs were administered, as dictated by the
reatment protocol.
Table 2 shows the incidence of acute lung injury
or amifostine-treated and placebo groups. As can be
able 1. Patient Characteristics by Treatment Center
Variable Colorado Stanford Karmanos Total
34 32 12 78
ge, y, mean (SD) 45 (9) 46 (8) 46 (6) 46 (8)
tage II, n (%) 32 (94) 28 (88) 10 (83) 70 (90)
nterval,* d (SD)
Amifostine 78 (62) 52 (9) 66 (44) 63 (40)
Placebo 77 (60) 58 (35) 34 (28) 64 (50)
Total 77 (59) 55 (25) 58 (42) 63 (43)
Interval—the time in days between the completion of STAMP I
and the diagnosis of acute lung injury.een, no signiﬁcant differences were noted between
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Acute Lung Injury and Amifostine
Broups. In fact, the absolute incidence of acute lung
njury in the amifostine-treated group (77%) exceeded
hat of the placebo group (64%; P  .46). The overall
ncidence of diagnosed acute lung injury was 71%.
he incidences of acute lung injury from patients
reated at Stanford (27/32; 84%), Karmanos (8/12;
7%), and Colorado (20/34; 59%) all exceeded his-
orical data on the incidence of acute lung injury
roduced by the STAMP I regimen.
Table 3 shows the PK data from the treatment and
lacebo groups. No signiﬁcant differences between
he BCNU area under the plasma disappearance curve
AUC) and maximal plasma concentration were seen.
lthough amifostine was administered after cyclo-
hosphamide and 95% of the cisplatin had been ad-
inistered, we evaluated the possibility that that there
ere differences in cyclophosphamide or cisplatin PK
etween the 2 groups. No such differences were ob-
erved (data not shown).
If amifostine produced a partial protective effect, it
ould be reasonable to hypothesize that the intervals
rom BCNU treatment to the diagnosis of acute lung
njury might be longer for patients receiving amifos-
ine (63 days) than for placebo (63 days), but they were
dentical. All surviving patients were observed for 6
onths for acute lung injury. The median  SD of
he time to development of acute lung injury was 63
3 days, strongly suggesting that it is likely that 5%
f acute lung injury diagnoses were missed because of
his design feature.
Seventy of the 78 patients evaluable in this study
ere treated in the adjuvant setting. This factor, and
he previously described study design, do not permit
nalysis of tumor outcome between the 2 groups.
inally, 1 of the 78 patients died as a result of acute
ung injury. This patient received amifostine. One
ther patient died of nonpulmonary regimen-related
oxicity, for a total toxicity mortality rate of 3%.
ISCUSSION
Under the conditions used in this study, the ad-
inistration of 2 conventional doses of amifostine
efore the BCNU used in the STAMP I regimen did
able 2. Frequency of Diagnosis of Acute Lung Injury by Center and
reatment Group
Amifostine Colorado Stanford Karmanos Total
otal 34 32 12 78
ALI, n (%) 20 (59) 27 (84) 8 (67) 55 (71)
mifostine 16 15 8 39
ALI, n (%) 10 (63) 14 (93) 6 (75) 30 (77)
lacebo 18 17 4 39
ALI, n (%) 10 (56) 13 (76) 2 (50) 25 (64)
LI indicates acute lung injury.ot protect against acute lung injury. This was the ﬁrst
B&MTrial designed to test this tissue-protective activity.
lthough numerous other randomized and phase II
rials have suggested protection against peripheral
europathy, ototoxicity, marrow toxicity, gastrointes-
inal mucositis, and other tissues by both chemother-
py and radiation, no such beneﬁt was observed in this
tudy. In fact, the study was stopped after a planned
nterim analysis suggested the high probability that
he trial would be negative.
The STAMP I regimen was used primarily to treat
atients with breast cancer. A recent randomized trial,
resented in abstract form, questioned the beneﬁt of
his treatment in a study containing older patients
han those reported here [16]. Although this result
ay lessen the clinical importance of STAMP I,
CNU is used routinely for hematopoietic cell–sup-
orted treatment of lymphoma in both the cyclophos-
hamide, BCNU, and VP-16 [17] and BCNU, etopo-
ide, cytarabine, and melphalan [18] regimens, for
xample. Thus, the toxicity question asked here has
ngoing and signiﬁcant clinical relevance. The trial
esign did not include relapse or survival as end
oints, because considerable data exist that show that
mifostine does not aversely affect these parameters
19] and because the predominance of primary breast
ancer included in this trial would require prolonged
ollow-up and, likely, larger patient numbers for
eaningful analysis.
Several factors could be responsible for our failure
o observe lung protection: (1) failure to administer
mifostine in an optimal manner, (2) lack of correla-
ion between BCNU dose and pulmonary injury pro-
uced by STAMP I, (3) failure of amifostine to neu-
ralize BCNU or its metabolites in lung tissue for
hemical or pharmacodynamic reasons, (4) failure to
iagnose acute lung injury uniformly between the 2
atient groups, or (5) overdiagnosis of acute lung
njury with sufﬁcient frequency to obscure any pro-
ective effect of amifostine.
Amifostine has been shown to be distributed to a
ariety of normal tissues, including the lung, and hy-
rolyzed rapidly to its active metabolite WR-1065 [7].
asserman et al. [20] showed that amifostine pro-
able 3. Derived Pharmacokinetic Parameters for BCNU by
reatment Group*
Variable
AUC
(g-min/mL)
T1/2elim
(min)
Cmax
(g/mL)
mifostine, mean (SD) 415 (74) 15 (8) 3.4 (0.6)
lacebo, mean (SD) 456 (150) 18 (8) 3.7 (1.3)
UC indicates area under the plasma disappearance curve; T1/2elim,
elimination half-life; Cmax, maximal plasma concentration.
A total of 15 patients receiving amifostine and 15 patients receiving
placebo from whom total pharmacokinetic data were available
were included in this analysis. All these patients were treated at
the University of Colorado.
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2ided signiﬁcant cytoprotection to ex vivo cultured
ematopoietic progenitors treated with BCNU, dem-
nstrating that chemically, the concept of amifostine
roviding cytoprotection from BCNU was reason-
ble.
Amifostine is typically administered in a dose be-
ween 740 and 910 mg/m2 given 30 minutes before
hemotherapy. This trial was initiated in a period
hen the 740 mg/m2 dose was recommended, so it
as used for this study. This dose produces an average
lasma amifostine AUC of 1100 mol-min/L,
hereas the BCNU AUC from STAMP I is typically
400 mol-min/L. Because the active metabolite of
mifostine, WR-1065 [7], is hypothesized to neutral-
ze reactive intermediates by 1:1 covalent binding, 2
oses of amifostine were administered in this study to
nsure that approximately equal molar equivalents
CNU and amifostine were given to the study sub-
ects. Hydrolysis of BCNU, however, produces a
ighly reactive 2-chloroethyl-carbonium ion, as well
s 2-chloroethyl isocyanate, both of which could react
ith WR-1065 (Figure 1). Although it is generally
uggested that glutathione reacts substantially with
he isocyanate but not the carbonium ion [21], it is
ossible that the dose of amifostine was insufﬁcient to
eutralize the drug in lung tissue. Further, carbonium
ons, because of their instability, cannot circulate after
ormation, but rather will react with the closest mol-
cule possessing a negative charge. Thus, they might
roduce their effects primarily intracellularly. The
socyanate, however, has a half-life of a few minutes in
he circulation and thus might primarily act at the cell
embrane if the primary site of BCNU hydrolysis is
Figure 1. R1  2-ethyl-[3 aminopropyl aminoethyl].ntravascular. d
80Others have suggested that the conjugation of
-chloroethyl isocyanate with glutathione is reversible
nd that the conjugate, in effect, may stabilize the
socyanate and enhance its toxicity [22]. The chemical
ctivity of WR-1065 mimics the activity of glutathi-
ne. Because WR-1065 exists primarily in the intra-
ellular space, it is possible that WR-1065, the active
etabolite of amifostine, exists in a low concentration
t the cell membrane, where the isocyanate might
roduce its toxic effects. It is reasonable to hypothe-
ize that 2-chloroethyl isocyanate might be the pri-
ary cause of BCNU-induced lung injury, because its
lose chemical cousin, methyl isocyanate, was the
ause of extensive pulmonary injury after a well-pub-
icized industrial accident in Bhopal, India (ICMR
eport [1986] Health effects of the Bhopal gas trag-
dy. Indian Council of Medical Research, New Delhi)
23]. It seems likely that attempts to substantially in-
rease the dose of amifostine to compensate for these
actors might produce unacceptable hypotension, the
ell-recognized acute toxicity of amifostine.
BCNU is widely recognized as a pulmonary toxin
24]. When administered in hematopoietic cell trans-
lant doses, a syndrome of acute lung injury is fre-
uently seen [9,12,25,26]. The injury manifests as dys-
nea, cough, and fever or as asymptomatic
bnormalities in pulmonary function tests. The chest
adiograph is most often normal. This injury most
requently occurs between 1 and 3 months, and rarely
ater than 6 months, after BCNU treatment. The
njury is highly corticosteroid responsive if diagnosed
arly, and the natural history of the injury after
TAMP I has been described in detail. Some reports
27], but not others [11], have described a pharmaco-
ynamic relationship between the BCNU AUC and
ulmonary drug injury when the STAMP I regimen is
sed. Because the incidence of lung injury produced
y cyclophosphamide or cisplatin when used as single
gents in comparable doses is small, it seems unlikely
hat they cause the lung injury produced by STAMP I.
urther, comprehensive analyses of the PK of
TAMP I suggest that, in the same patients in whom
harmacodynamic correlations between BCNU and
ung injury occur, there is no correlation with the PK
f either cyclophosphamide or cisplatin [27]. These
ata, taken together, suggest that the administration
f amifostine before BCNU represents a reasonable
harmacologically designed attempt to provide lung
ytoprotection from STAMP I.
Finally, the STAMP I regimen and its acute lung
njury syndrome are well recognized and described.
atients treated with STAMP I were carefully in-
tructed to report dyspnea, cough, or fever to their
ersonal oncologists or transplant center physicians at
nce. They were provided with written instructions to
ransmit to physicians caring for them at home about
iagnosis and treatment of the lung injury. The inci-
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Acute Lung Injury and Amifostine
Bence of acute lung injury reported for both the ami-
ostine- and placebo-treated groups in this trial varied
omewhat among the 3 participating centers. Most
otably, however, the incidence of clinically diagnosed
cute lung injury was higher in all 3 centers than the
requency anticipated from historical data. To evalu-
te the possibility that overdiagnosis of acute lung
njury might have obscured the analysis, we inspected
he subset of 34 patients treated at the University of
olorado, whose frequency of diagnosis of acute lung
njury was the lowest and most comparable to histor-
cal data (59%). In this subgroup, the frequencies of
cute lung injury in patients treated with amifostine
10/16; 63%) and placebo (10/18; 56%) were compa-
able (P  .74), suggesting that neither overdiagnosis
or amifostine use could explain the outcome re-
orted here.
In conclusion, we were unable to detect any re-
uction in acute lung injury associated with the
TAMP I regimen as a result of amifostine adminis-
ration. This result should be viewed as speciﬁcally
elating to the BCNU used in STAMP I, and it does
ot reﬂect on the ability of amifostine to provide
ytoprotection with other agents or regimens. We do
ot believe, however, that altering the dose or sched-
le of amifostine is likely to enhance amifostine cyto-
rotection from BCNU-associated acute lung injury.
he high frequency of acute lung injury observed in
his study reinforces this view. Further studies of ami-
ostine/BCNU combinations should be conducted
nly after careful attention to the results presented
ere.
EFERENCES
1. Capizzi RAmifostinethe preclinical basis for broad-spectrum
selective cytoprotection of normal tissues from cytotoxic ther-
apies. Semin Oncol. 1996;23(4 suppl 8):2-17.
2. Kemp G, Rose P, Berman M, et al. Amifostine pretreatment for
protection against cyclophosphamide-induced and cisplatin-in-
duced toxicities: results of a randomized control trial in patients
with advanced ovarian cancer. J Clin Oncol. 1996;14:2101-2112.
3. Buntzel J, Schuth J, Kuttner K, Glatzel M. Radiochemotherapy
with amifostine cytoprotection for head and neck cancer. Sup-
port Care Cancer. 1998;6:155-160.
4. Phillips GL. The potential of amifostine in high-dose chemo-
therapy and autologous hematopoietic stem cell transplanta-
tion. Semin Oncol. 2002;29(6 suppl 19):53-56.
5. Mollman JE, Glover DJ, Hogan WM, et al. Cisplatin neuro-
toxicity. Risk factors, prognosis, and protection by WR-2721.
Cancer. 1988;61:2192-2195.
6. Tannehill SP, Mehta MP, Larson M, et al. Effect of amifostine
on toxicities associated with sequential chemotherapy and ra-
diation therapy for unresectable non-small-cell lung cancer:
results of a phase II trial. J Clin Oncol. 1997;15:2850-2857.
7. Capizzi RL. The preclinical basis for broad-spectrum selective
cytoprotection of normal tissues from cytotoxic therapies by
amifostine. Semin Oncol. 1999;26(2 suppl 7):3-21. 2
B&MT8. Capizzi RL, Oster W. Chemoprotective and radioprotective
effects of amifostine: an update of clinical trials. Int J Hematol.
2000;72:425-435.
9. Cao TM, Negrin RS, Stockerl-Goldstein K, et al. Pulmonary
toxicity syndrome in breast cancer patients undergoing BCNU-
containing high-dose chemotherapy and autologous hemato-
poietic cell transplantation. Biol Blood Marrow Transplant. 2000;
6:387-394.
0. Jones RB, Matthes S, Shpall EJ, et al. Acute lung injury follow-
ing treatment with high-dose cyclophosphamide, cisplatin, and
carmustine: pharmacodynamic evaluation of carmustine. J Natl
Cancer Inst. 1993;85:640-647.
1. Wilczynski SW, Erasmus JJ, Petros WP, Vredenburgh JJ, Folz
RJ. Delayed pulmonary toxicity syndrome following high-dose
chemotherapy and bone marrow transplantation for breast can-
cer. Am J Respir Crit Care Med. 1998;157:565-573.
2. Chap L, Shpiner R, Levine M, Norton L, Lill M, Glaspy J.
Pulmonary toxicity of high-dose chemotherapy for breast can-
cer: a non-invasive approach to diagnosis and treatment. Bone
Marrow Transplant. 1997;20:1063-1067.
3. Rubio C, Hill ME, Milan S, O’Brien ME, Cunningham D.
Idiopathic pneumonia syndrome after high-dose chemotherapy
for relapsed Hodgkin’s disease. Br J Cancer. 1997;75:1044-1048.
4. Peters WP, Shpall EJ, Jones RB, et al. High-dose combination
alkylating agents with bone marrow support as initial treatment
for metastatic breast cancer. J Clin Oncol. 1988;6:1368-1376.
5. Jones RB, Matthes S, Shpall EJ, et al. BCNU pharmacokinetics
in 72 patients treated with high-dose combination chemother-
apy and autologous bone marrow support. Analytical method-
ology and patient data. J Chromatogr Biomed. 1994.
6. Peters WP, Rosner G, Vredenburgh J, et al. A prospective,
randomized comparison of two doses of combination alkylating
agents (AA) as consolidation after CAF in high-risk primary
breast cancer involving ten or more axillary lymph nodes (LN):
preliminary results of CALGB 9082/SWOG 9114/NCIC
MA-13 [meeting abstract]. Proc Am Soc Clin Oncol. 1999;18:1a.
7. Zander AR, Culbert S, Jagannath S, et al. High-dose cyclo-
phosphamide, BCNU, and VP-16 (CBV) as a conditioning
regimen for allogeneic bone marrow transplantation for pa-
tients with acute leukemia. Cancer. 1987;59:1083-1096.
8. Chopra R, McMillan AK, Linch DC, et al. The place of high-
dose BEAM therapy and autologous bone marrow transplanta-
tion in poor-risk Hodgkin’s disease. A single-center eight-year
study of 155 patients. Blood. 1993;81:1137-1145.
9. Alberts DS, Speicher LA, Krutzsch M, et al. WR-1065, the
active metabolite of amifostine (Ethyol), does not inhibit the
cytotoxic effects of a broad range of standard anticancer drugs
against human ovarian and breast cancer cells. Eur J Cancer.
1996;32A(suppl 4):S17-S20.
0. Wasserman TH, Phillips TL, Ross G, Kane L. Differential
protection against chemotherapeutic effects on bone marrow
CFUs by WR-2721. Cancer Clin Trials. 1981;4:3-6.
1. Becker K, Schirmer RH. 1,3-Bis(2-chloroethyl)-1-nitrosourea
as thiol-carbamoylating agent in biological systems. Methods
Enzymol. 1995;251:173-188.
2. Davis MR, Kassahun K, Jochheim CM, Brandt KM, Baillie TA.
Glutathione and N-acetylcysteine conjugates of 2-chloroethyl
isocyanate. Identiﬁcation as metabolites of N,N-bis(2-chloro-
ethyl)-N-nitrosourea in the rat and inhibitory properties to-
ward glutathione reductase in vitro. Chem Res Toxicol. 1993;6:
376-383.3. Sriramachari S, Jeevaratnam K. Comparative toxicity of methyl
281
22
2
2
R. B. Jones et al.
2isocyanate and its hydrolytic derivatives in rats. Arch Toxicol.
1994;69:45-51.
4. Durant JR, Norgard NJ, Murad TM, Bartolucci AA, Langford
KH. Pulmonary toxicity associated with bischloroethylnitro-
sourea (BCNU). Ann Intern Med. 1979;90:191-194.
5. Seiden MV, Elias A, Ayash L, et al. Pulmonary toxicity associated
with high dose chemotherapy in the treatment of solid tumors
with autologous marrow transplant: an analysis of four chemother-
apy regimens. Bone Marrow Transplant. 1992;10:57-63.826. Todd NW, Peters WP, Ost AH, Roggli VL, Piantadosi CA.
Pulmonary drug toxicity in patients with primary breast cancer
treated with high-dose combination chemotherapy and autol-
ogous bone marrow transplantation. Am Rev Respir Dis. 1993;
147:1264-1270.
7. Jones RB, Matthes S, Shpall EJ, et al. Acute lung injury follow-
ing high-dose cyclophosphamide, cisplatin and BCNU. Phar-
macodynamic evaluation of BCNU. J Natl Cancer Inst. 1993;
85:640-647.
